248 related articles for article (PubMed ID: 29120519)
1. Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.
Inubushi T; Lemire I; Irie F; Yamaguchi Y
J Bone Miner Res; 2018 Apr; 33(4):658-666. PubMed ID: 29120519
[TBL] [Abstract][Full Text] [Related]
2. A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
Matsumoto K; Irie F; Mackem S; Yamaguchi Y
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10932-7. PubMed ID: 20534475
[TBL] [Abstract][Full Text] [Related]
3. Osteochondroma formation is independent of heparanase expression as revealed in a mouse model of hereditary multiple exostoses.
Mundy C; Chung J; Koyama E; Bunting S; Mahimkar R; Pacifici M
J Orthop Res; 2022 Oct; 40(10):2391-2401. PubMed ID: 34996123
[TBL] [Abstract][Full Text] [Related]
4. Multiple hereditary exostoses (MHE): elucidating the pathogenesis of a rare skeletal disorder through interdisciplinary research.
Jones KB; Pacifici M; Hilton MJ
Connect Tissue Res; 2014 Apr; 55(2):80-8. PubMed ID: 24409815
[TBL] [Abstract][Full Text] [Related]
5. Signaling systems affecting the severity of multiple osteochondromas.
Piombo V; Jochmann K; Hoffmann D; Wuelling M; Vortkamp A
Bone; 2018 Jun; 111():71-81. PubMed ID: 29545125
[TBL] [Abstract][Full Text] [Related]
6. Heparan sulfate deficiency leads to hypertrophic chondrocytes by increasing bone morphogenetic protein signaling.
Kawashima K; Ogawa H; Komura S; Ishihara T; Yamaguchi Y; Akiyama H; Matsumoto K
Osteoarthritis Cartilage; 2020 Nov; 28(11):1459-1470. PubMed ID: 32818603
[TBL] [Abstract][Full Text] [Related]
7. The short-lived exostosis induced surgically versus the lasting genetic hereditary multiple exostoses.
Trebicz-Geffen M; Nevo Z; Evron Z; Posternak N; Glaser T; Fridkin M; Kollander Y; Robinson D
Exp Mol Pathol; 2003 Feb; 74(1):40-8. PubMed ID: 12645631
[TBL] [Abstract][Full Text] [Related]
8. HSPG-deficient zebrafish uncovers dental aspect of multiple osteochondromas.
Wiweger MI; Zhao Z; van Merkesteyn RJ; Roehl HH; Hogendoorn PC
PLoS One; 2012; 7(1):e29734. PubMed ID: 22253766
[TBL] [Abstract][Full Text] [Related]
9. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.
Jones KB; Piombo V; Searby C; Kurriger G; Yang B; Grabellus F; Roughley PJ; Morcuende JA; Buckwalter JA; Capecchi MR; Vortkamp A; Sheffield VC
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2054-9. PubMed ID: 20080592
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of the EXT2 gene in developing chondrocytes enhances the synthesis of heparan sulfate and bone formation in mice.
Morimoto K; Shimizu T; Furukawa K; Morio H; Kurosawa H; Shirasawa T
Biochem Biophys Res Commun; 2002 Apr; 292(4):999-1009. PubMed ID: 11944914
[TBL] [Abstract][Full Text] [Related]
11. An optimized DHPLC protocol for molecular testing of the EXT1 and EXT2 genes in hereditary multiple osteochondromas.
Wuyts W; Radersma R; Storm K; Vits L
Clin Genet; 2005 Dec; 68(6):542-7. PubMed ID: 16283885
[TBL] [Abstract][Full Text] [Related]
12. No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.
Reijnders CM; Waaijer CJ; Hamilton A; Buddingh EP; Dijkstra SP; Ham J; Bakker E; Szuhai K; Karperien M; Hogendoorn PC; Stringer SE; Bovée JV
Am J Pathol; 2010 Oct; 177(4):1946-57. PubMed ID: 20813973
[TBL] [Abstract][Full Text] [Related]
13. Heparan sulfate antagonism alters bone morphogenetic protein signaling and receptor dynamics, suggesting a mechanism in hereditary multiple exostoses.
Mundy C; Yang E; Takano H; Billings PC; Pacifici M
J Biol Chem; 2018 May; 293(20):7703-7716. PubMed ID: 29622677
[TBL] [Abstract][Full Text] [Related]
14. Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.
Zak BM; Schuksz M; Koyama E; Mundy C; Wells DE; Yamaguchi Y; Pacifici M; Esko JD
Bone; 2011 May; 48(5):979-87. PubMed ID: 21310272
[TBL] [Abstract][Full Text] [Related]
15. Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple Exostoses.
Huegel J; Mundy C; Sgariglia F; Nygren P; Billings PC; Yamaguchi Y; Koyama E; Pacifici M
Dev Biol; 2013 May; 377(1):100-12. PubMed ID: 23458899
[TBL] [Abstract][Full Text] [Related]
16. Cell biology of osteochondromas: bone morphogenic protein signalling and heparan sulphates.
Cuellar A; Reddi AH
Int Orthop; 2013 Aug; 37(8):1591-6. PubMed ID: 23771188
[TBL] [Abstract][Full Text] [Related]
17. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas.
Hameetman L; David G; Yavas A; White SJ; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
J Pathol; 2007 Mar; 211(4):399-409. PubMed ID: 17226760
[TBL] [Abstract][Full Text] [Related]
18. [From gene to disease; hereditary multiple exostoses].
Wuyts W; Bovée JV; Hogendoorn PC
Ned Tijdschr Geneeskd; 2002 Jan; 146(4):162-4. PubMed ID: 11845565
[TBL] [Abstract][Full Text] [Related]
19. Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity.
Cheung PK; McCormick C; Crawford BE; Esko JD; Tufaro F; Duncan G
Am J Hum Genet; 2001 Jul; 69(1):55-66. PubMed ID: 11391482
[TBL] [Abstract][Full Text] [Related]
20. A broad spectrum of genomic changes in latinamerican patients with EXT1/EXT2-CDG.
Delgado MA; Martinez-Domenech G; Sarrión P; Urreizti R; Zecchini L; Robledo HH; Segura F; de Kremer RD; Balcells S; Grinberg D; Asteggiano CG
Sci Rep; 2014 Sep; 4():6407. PubMed ID: 25230886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
